INDV Indivior Pharmaceuticals, Inc.
Legal ·
Indivior Pharmaceuticals, Inc. is the named defendant in the Northern District of Ohio MDL. Canadian class actions name subsidiaries, and a qui tam case names Indivior Inc.
Supernus and Indivior agreed to an all-stock merger that includes a $1.0 billion cash dividend to Indivior stockholders. The companies say a $650 million Citibank term loan commitment will help fund it, and they expect the deal to close in the fourth quarter of 2026.
The company amended its November 4, 2024 note purchase agreement to reflect that Indivior U.S. now reports the financials. The board carries over, and a 2026 equity plan reserves 17,500,000 shares.
Indivior says its Action Agenda initiative brings headcount reductions and real estate consolidations. It expects $27 million to $35 million of the charges to be cash and is exploring strategic alternatives for OPVEE and its non-U.S. business.
Indivior Pharmaceuticals, Inc. is a market leader in long-acting injectable medications for opioid use disorder (OUD). Its core approved treatments are SUBLOCADE (buprenorphine extended-release monthly injection) and SUBOXONE Film (buprenorphine and naloxone sublingual film). The U.S. accounted for 85% of net revenues in 2025, and in the U.S. the company sells only SUBLOCADE and SUBOXONE Film. SUBUTEX Tablets are distributed primarily in Australia, France and Germany, and SUBOXONE Tablets continue on a transition basis in a limited number of countries. The company's product pipeline includes two new drug candidates for the treatment of OUD. The business was developed as a division of Reckitt Benckiser Group PLC and became standalone after the demerger effective December 23, 2014. On January 23, 2026, Indivior Pharmaceuticals, Inc. became the ultimate parent company of Indivior PLC through a court-approved scheme of arrangement, completing a U.S. domestication. In 2020 the company reached agreements with the Department of Justice and the Federal Trade Commission concerning SUBOXONE marketing and promotional practices.
| Product or program | What it is | Stage |
|---|---|---|
| SUBLOCADE | Monthly buprenorphine extended-release injection for OUD | approved |
| SUBOXONE Film | Buprenorphine and naloxone sublingual film for OUD | approved |
| SUBUTEX Tablets | Buprenorphine sublingual tablet distributed primarily outside the U.S. |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.24 billion | $1.19 billion |
| Research and development | $97.0 million | $107.0 million |
| Net income (loss) | $210.0 million | $7.0 million |
| Cash from operations | -$27.0 million | $36.0 million |
| Cash and equivalents | $195.0 million | $319.0 million |
| Short-term investments | $0 | $1.0 million |
Our latest story on this, dated Oct 29, 2026: "Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028". The story links the filing or release it is based on. Read the story.
Indivior Pharmaceuticals, Inc. trades under the ticker INDV on NASDAQ.
Indivior Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:E7P; FWB:E7P; GETTEX:E7P; LS:A42086; LSX:A42086; MUN:E7P; TRADEGATE:E7P; XETR:E7P.
The SEC Central Index Key (CIK) for Indivior Pharmaceuticals, Inc. is 1625297. Its filings are on SEC EDGAR.
118,013,649 shares as of 2026-07-28, per the cover page of its 10-Q filed 2026-08-03.
Our directory records Indivior Pharmaceuticals, Inc. under United States.
Our directory classifies Indivior Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Indivior Pharmaceuticals, Inc. is US45579U1097.
aibio.space lists Indivior Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Indivior Pharmaceuticals, Inc. is a market leader in long-acting injectable medications for opioid use disorder (OUD). Its core approved treatments are SUBLOCADE (buprenorphine extended-release monthly injection) and SUBOXONE Film (buprenorphine and naloxone sublingual film).
SUBLOCADE: Monthly buprenorphine extended-release injection for OUD Stage: approved.
SUBOXONE Film: Buprenorphine and naloxone sublingual film for OUD Stage: approved.
$1.24 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Indivior Pharmaceuticals, Inc. reported net income of $210.0 million for the fiscal year ended Dec 31, 2025, and used $27.0 million of cash in operations, per its annual report to the SEC.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Filed to end its SEC reporting. SEC Form 15-12G. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Announced a share repurchase program. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio